Eflapegrastim

Phase 2Protein / enzyme

Spectrum Pharmaceuticals, Inc

Eflapegrastim is one of 39 biologic programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Solid TumorPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Navmi

SSummit Therapeutics

Preclinical

1 8

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

Tulmimetostat

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Solid Tumor

NCT04570423

Clinical

Trials by Indication[1]

Neutropenia2 trials

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 1·NCT04187898·59 enrolled

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Unknown status·—·Phase 4·NCT05949333·100 enrolled

Solid Tumor1 trial

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Recruiting· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT04570423·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Eflapegrastim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eflapegrastim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eflapegrastim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Spectrum Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: Spectrum Pharmaceuticals, Inc

Eflapegrastim

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neutropenia2 trials

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News